newsfilter
← Latest News
PR Newswire·

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

LONDON, Jan. 11, 2022 /PRNewswire/ -- LumiraDx (NASDAQ:LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.